Sesen Bio — Merger or Acquisition (February 2023)
17 slides from Sesen Bio's merger presentation, Feb 2, 2023
Slide 1: Maximizing Value for Sesen Bio Stockholders
Maximizing Value for Sesen Bio Stockholders February 2023
Slide 2: Forward-Looking Statements and Additional Disclaimers
Forward - Looking Statements and Additional Disclaimers Forward - Looking Statements Any statements in this communication about future expectations, plans and prospects for Sesen Bio, Inc. ( Sesen Bio), CARISMA Therapeutics Inc. ( Carisma ) or the combined company, Sesen Bio’s, Carisma’s or the comb
Slide 3: Sesen Bio-Carisma Merger Delivers Compelling Value to Stockholders
• Sesen Bio stockholders to immediately own 25.2% stake in $357M combined company 3 • Significant long - term upside through Carisma’s proprietary CAR - M platform , entirely novel immunotherapy approach that has the potential to change the way cancer and other serious diseases are treated • Led by
Slide 4: Implied total value per share: dividend, pro forma stake and CVR
1 Reflects pro forma company value including stated valuation for Sesen Bio, Carisma , and fully diluted value of the Moderna convertible note 2 Amounts reflect potential payments in the future and have not been discounted. Does not include potential proceeds from Vicineum or the Company’s other leg
Slide 5: Amended merger agreement delivers even greater value in connection with closing
Amended merger agreement delivers even greater value in connection with closing $30M CVR $30M CVR with Additional Upside Up to $25M ( $0.12 per share) ~$70M ( $0.34 per share) Enhanced Special Cash Dividend Expanded CVR Original Merger Agreement Amended Merger Agreement Original Merger Agreement Ame
Slide 6: Engaged extensively with Investor Group; Investor Group unwilling to budge
Engaged extensively with Investor Group and negotiated heavily with Carisma to reach ~$70M special dividend , $45M increase from original merger agreement $25M $40M $65M $70M Increasing Dividend Offers Investor Group Dividend Offers $100M $92M • Investor Group continues to be opportunistic and singl
Slide 7: Transaction Compares Favorably to Precedent Reverse Merger Transactions
Four - month strategic review process spanned 12 Board meetings *Source: SEC filings of reverse merger transactions 2020 - 2022 1 Average is of the 42 bids received 25.2% Ownership percentage of reverse merger company 30% $15M Reverse merger company value $13.3M 1 50% Cash contribution from reverse
Slide 8: Four-month strategic review process spanned Board meetings
Independent and value creation focused Board with decades of experience in leadership positions within life sciences and biotech and significant transaction experience April 22, 2022 Initiated comprehensive strategic alternatives review process May 18, 2022 – June 7, 2022 Conducted proactive outreac
Slide 9: Implied per share value does not reflect potential Vicineum sale value
$0.88 implied per share value of pending merger with Carisma does not reflect any additional potential value from the sale of Vicineum or other legacy assets. Any proceeds received from a potential sale would be additional upside for Sesen Bio stockholders. Today: Given ongoing discussions with pote
Slide 10: The Investor Group is Not Acting in The Best Interests of All Stockholders
The Investor Group is Not Acting in The Best Interests of All Stockholders 10 • Built current position after merger was announced . Investor Group failed to articulate a plan for the Company beyond rejecting the merger. They also refused multiple opportunities to meet Carisma management team to lear
Slide 11: Extensive Good Faith Negotiations with Investor Group
Increased special dividend three times as part of negotiations, increasing it by more than 180% Extensive Good Faith Negotiations with Investor Group in Direct Response to Requests 11 September 21, 2022 Sesen Bio announces proposed merger with Carisma November 18, 2022 Investor group files initial 1
Slide 12: Carisma: Cutting edge research and bioengineering
Cutting edge research and bioengineering: • Proprietary platform for macrophage targeted therapies • First - in - human study of CAR - Macrophages • Autologous/ allogeneic/ in - vivo modalities • Broad potential therapeutic applications, in oncology and beyond Strong patent position covering all CAR
Slide 13: Carisma: Valuation is Attractive and Supported by Rigorous Analysis
Attractive Discounted Cash Flow Value Implied equity value 1 range of ~$225M to ~$335M, above $196M proposed Carisma valuation 2 Leader in the CAR - M Space Believed to be the only company to have demonstrated proof of mechanism and safety data in this therapy through human clinical trials Strategic
Slide 14: Carisma: Strong Patent Position
Worldwide patent coverage with issued and pending applications in major markets Multiple issued U.S. patents covering CAR - M composition of matter Broad patent portfolio covering: • Viral and non - viral methods for engineering monocytes and macrophages • Methods for treatment of protein aggregate
Slide 15: Carisma: Moderna Partnership
Promising data emerging with rapid execution on lead programs • Multiple development programs initiated, with goal of adding 2 - 3 new programs/year • LNP delivery demonstrating high specificity to myeloid cells and ability to re - dose • High CAR expression, viability, and CAR - M function • Animal
Slide 16: Carisma's Management Team, Board of Directors and Key Advisors
DANIEL CUSHING, PHD Chief Technology & Development Officer STEVEN KELLY President & CEO MICHAEL KLICHINSKY, PHD Co - Founder & CSO RICHARD MORRIS Chief Financial Officer TOM WILTON Chief Business Officer Carisma’s Management Team Board of Directors • Steve Kelly – President & CEO • Sanford Zweifach
Slide 17: Board conducted robust process; best available option for stockholders
Board conducted robust process and no stone was left unturned. C ontacted 100+ parties . Explored every possible scenario. Every time, the pending merger with Carisma delivered the most value for stockholders. This is the best available option for stockholders: O nly remaining viable alternative is